New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar® (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary liver cancer.
Read more ...
Novo Nordisk joins the Call to Action for gender equality
Yesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørnæs makes a Call to Action to leaders from around the world to help accelerate progress on the Millennium Development Goal 3 (MDG3): To empower women and promote gender equality.
Read more ...
DAIICHI SANKYO continues its expansion in Germany and Europe
At the beginning of August, DAIICHI SANKYO DEUTSCHLAND GmbH is planning to take over most of the sales force for primary-care physicians in Germany used by Merck Pharma GmbH and to integrate them into the existing sales structure. The agreement between the German subsidiary of the third-largest Japanese pharmaceutical group and the Darmstadt-based company will affect about 130 employees.
Read more ...
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance
Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
Read more ...
Nycomed - strong results in second quarter 2008
In the first six months of 2008, Nycomedâs adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effects of last yearâs restructuring and as a result of the successful integration.
Read more ...
Divestment of four Roche pharmaceutical products to Meda
Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wide product rights for Marcoumar (Anticoagulant), Torem (Loop diuretic), Tilcotil (painful musculoskeletal disorders) and Aurorix (Depression) are being transferred to Meda for a total amount of 120 million Euros.
Read more ...
AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR®
AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.
Read more ...